AH: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
Ad hoc announcement - Insider information pursuant to Article 17 MAR
Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
Ladenburg, Germany, 9 September 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH and Takeda signed a license agreement granting Takeda an exclusive license to commercially develop an Antibody Targeted Amanitin Conjugate directed to a previously selected target molecule.
Takeda obtained access to Heidelberg Pharma's proprietary Amanitin toxin-linker platform technology under an exclusive multi-target research agreement effective as of June 2017. Takeda provided different antibodies to Heidelberg Pharma to generate new ATACs®. ATACs® are ADCs (Antibody Drug Conjugates) based on Heidelberg Pharma's ATAC® technology.
+++ End of the ad hoc announcement +++